ClinicalTrials.gg
CompletedNCT03934814Updated Jul 1, 2024

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

A Phase 1 interventional study of TJ011133 and Pembrolizumab in Solid Tumor and Lymphoma, sponsored by I-Mab Biopharma US Limited. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by I-Mab Biopharma US Limited · Phase 1, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
303rd of 1,595
98 · median 36
Started
2019
with 48 others
Phase 1
582 of 1,910
37 open now
Registered
1,572nd of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 303rd largest by enrollment of the 1,595 interventional ones that give a count, is one of 49 that started in 2019, is one of 582 in phase 1, and was the 1,572nd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Read the detailed description

This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety, tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an anti-CD47 antibody, in participants with advanced relapsed or refractory solid tumors and lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.

03

Conditions studied

  • Solid Tumor
  • Lymphoma

Browse trials for

Keywords

  • Solid Tumor
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Participants with advanced solid tumors and lymphoma.
  • Part 2 with Rituximab: Participants with diffuse large B-cell lymphoma (DLBCL) or Indolent B-cell Lymphoma, with at least one by Lugano and available fresh sample prior to study entry.
  • Part 2 with Pembrolizumab: Participants with locally advanced non-small-cell lung carcinoma (NSCLC) with disease progression or immune-oncology treatment naive Epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with at least one measurable lesion defined by Response Elevation Criteria in Solid Tumors () 1.1, and available fresh metastatic biopsy prior to study entry.
  • All Parts: (ECOG) Performance Status 0 to 1 and adequate bone marrow, renal, and liver functions.

Exclusion criteria

Exclusion Criteria:

  • Participants with known symptomatic central nervous system tumors or known central nervous system or requiring . Participants who document stable and central nervous system metastases and are off steroids for more than 4 weeks may be enrolled in the study.
  • Participants with Burkitt's lymphoma, lymphoblastic lymphoma, Richter's transformation, primary effusion lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Participants with mantle cell lymphoma.
  • Impaired cardiac function or cardiac diseases.
  • Prior treatment with 7 or SIRPα inhibitors.
  • Prior stem cell transplant \<=3 months prior to starting study.
  • Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.
  • Prior chimeric antigen receptor or chimeric antigen receptor T-cell therapy.
  • History of anemia or autoimmune thrombocytopenia.
  • Positive Direct Antiglobulin Test.
  • Active (GVHD) or ongoing for GVHD.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Part 1A - TJ011133 Monotherapy

    TJ011133 alone will be administered at up to 7 dose levels (0.3, 1, 3, 10, 20, 30, 45 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level).

    Drug: TJ011133

  • Experimental
    Part 1B - Combination therapy of TJ011133 with pembrolizumab

    TJ011133 will be administered Q1W, starting at 20 mg/ kg, in combination with pembrolizumab.

    Drug: TJ011133 · Drug: Pembrolizumab

  • Experimental
    Part 1C - Combination therapy of TJ011133 with rituximab

    TJ011133 will be administered Q1W, starting at 20 mg/kg, in combination with rituximab.

    Drug: TJ011133 · Drug: Rituximab

  • Experimental
    Part 2 - Dose Expansion

    30 participants (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 participants with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.

    Drug: TJ011133 · Drug: Pembrolizumab · Drug: Rituximab

Interventions

  • DrugLemzoparlimabStudies of LemzoparlimabLemzoparlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TJ011133 will be administered weekly.

  • Pembrolizumab will be administered every 3 weeks.

    Also known as: KEYTRUDA®

  • Rituximab will be administered weekly for 5 doses, then followed by monthly doses.

    Also known as: Rituxan, MabThera

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Part 1A DLT period is 3 weeks, Part 1B DLT period is 3 weeks, Part 1C DLT period is 4 weeks.

    Time frame: 21 or 28 days, depending on study part

  2. Incidence and Severity of Adverse Events

    The CTCAE criteria will be used to assess adverse events on this trial.

    Time frame: up to 100 days post last dose

  3. Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy

    Based on DLT definitions.

    Time frame: 21 or 28 days, depending on study part

  4. Change in Eastern Cooperative Oncology Group (ECOG) Performance Status

    Change in Eastern Cooperative Oncology Group (ECOG) Performance Status.

    Time frame: up to 100 days post last dose

Secondary outcomes

  1. Pharmacokinetic (PK): Area Under the Curve From Time Zero To Infinity (AUC∞)

    Area under the curve from time zero to infinity (AUC∞).

    Time frame: up to 100 days post last dose

  2. PK: Area Under the Curve From Time Zero To The Time Of The Last Quantifiable Concentration (AUC0-t)

    Area under the curve from time zero to the time of the last quantifiable concentration (AUC0-t).

    Time frame: up to 100 days post last dose

  3. PK: Maximum Observed Concentration (Cmax)

    Maximum observed concentration (Cmax).

    Time frame: up to 100 days post last dose

  4. PK: Time of the Maximum Observed Concentration (Tmax)

    Time of the maximum observed concentration (Tmax).

    Time frame: up to 100 days post last dose

  5. PK: Terminal Elimination Half-Life (T1/2)

    Investigational Product (IP) terminal elimination half-life (T1/2).

    Time frame: up to 100 days post last dose

  6. PK: Clearance (CL)

    Investigational Product (IP) Clearance (CL).

    Time frame: up to 100 days post last dose

  7. PK: Volume Of Distribution (Vz)

    Investigational Product (IP) volume of distribution (Vz).

    Time frame: up to 100 days post last dose

  8. PK: AUC Over A Dosing Interval (AUCtau)

    AUC over a dosing interval (AUCtau).

    Time frame: up to 100 days post last dose

  9. PK: Trough Concentration (Ctrough)

    Investigational Product (IP) trough concentration (Ctrough).

    Time frame: up to 100 days post last dose

  10. PK: Volume of Distribution at Steady State (Vss)

    Investigational Product (IP) volume of distribution at steady state (Vss).

    Time frame: up to 100 days post last dose

  11. Immunogenicity: Anti-drug antibodies (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: up to 100 days post last dose

  12. Efficacy: Best Overall Response (BOR)

    BOR is determined using Response Elevation Criteria in Solid Tumors (RECIST) 1.1 and immune Response Elevation Criteria in Solid Tumors (iRECIST) guidelines for response criteria for use in trials testing immunotherapeutics for solid tumors and Lugano criteria and lymphoma response to immunomodulatory therapy criteria (LYRIC) for lymphoma.

    Time frame: up to 100 days post last dose

  13. Efficacy: Objective Response Rate (ORR)

    ORR is determined using Response Elevation Criteria in Solid Tumors (RECIST) 1.1 and immune Response Elevation Criteria in Solid Tumors (iRECIST) guidelines for response criteria for use in trials testing immunotherapeutics for solid tumors and Lugano criteria and lymphoma response to immunomodulatory therapy criteria (LYRIC) for lymphoma.

    Time frame: up to 100 days post last dose

  14. Efficacy: Duration Of Response (DOR)

    DOR is determined using Response Elevation Criteria in Solid Tumors (RECIST) 1.1 and immune Response Elevation Criteria in Solid Tumors (iRECIST) guidelines for response criteria for use in trials testing immunotherapeutics for solid tumors and Lugano criteria and lymphoma response to immunomodulatory therapy criteria (LYRIC) for lymphoma.

    Time frame: up to 100 days post last dose

  15. Efficacy: Progression-Free Survival (PFS)

    PFS is determined using Response Elevation Criteria in Solid Tumors (RECIST) 1.1 and immune Response Elevation Criteria in Solid Tumors (iRECIST) guidelines for response criteria for use in trials testing immunotherapeutics for solid tumors and Lugano criteria and lymphoma response to immunomodulatory therapy criteria (LYRIC) for lymphoma.

    Time frame: up to 100 days post last dose

  16. Efficacy: Overall Survival (OS)

    OS is determined using Response Elevation Criteria in Solid Tumors (RECIST) 1.1 and immune Response Elevation Criteria in Solid Tumors (iRECIST) guidelines for response criteria for use in trials testing immunotherapeutics for solid tumors and Lugano criteria and lymphoma response to immunomodulatory therapy criteria (LYRIC) for lymphoma.

    Time frame: up to 100 days post last dose

07

Study locations

21 sites
  • University of Alabama - Birmingham
    Birmingham, Alabama 35233, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Horizon Oncology
    Lafayette, Indiana 47905, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Cancer Institute/Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • The Fourth Hpspital of Hebei Medical University(Hebei Cancer Hospital)
    Shijiazhuang, Hebei 50011, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • HuBei Cancer Hospital
    Wuhan, Hubei 430000, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300060, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jan 2023, 44 months.

Of 142 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 44 months is close to that.

Counting every sponsor, half of 280 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
May 2, 2019
StartActual
Apr 16, 2019
Primary completionActual
Jan 10, 2023
CompletionActual
Jan 10, 2023
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03934814
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
May 2, 2019
Start date
Apr 16, 2019
Primary completion
Jan 10, 2023
Completion
Jan 10, 2023
Last update
Jul 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemzoparlimab

Start the discussion